KOLEAN CRAWFORD: Open Payments
NPI 1073284642 · GRANBURY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$915 in 50 payments from 15 companies in 2025. Trend: 2023 $1,182 · 2024 $963 · 2025 $915
Food & beverage: $915
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $228 |
| ABBVIE INC. | 15 | $187 |
| Novo Nordisk Inc | 6 | $108 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Ardelyx, Inc. | 2 | $44 |
| Dexcom, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| PFIZER INC. | 2 | $42 |
| Exact Sciences Corporation | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
Products named: EVENITY, VRAYLAR, Ozempic, QULIPTA, AIRSUPRA, IBSRELA, Dexcom G6 Transmitter, REXULTI.
Industry payments across TX — which companies pay providers there.
